Access to medicinal products
Protecting citizens’ health through access to safe, effective and quality medicines is one of AIFA’s priority objectives. For this reason, the Agency is committed to guaranteeing the most appropriate medicines to all patients, regardless of social and economic conditions, in a timely and uniform manner throughout the country. Access to medicines presupposes an evaluation and authorisation process that can take place at European or national level.
National legislation provides for the possibility to grant, under specific conditions, early access to a medicinal product, even while undergoing clinical trials or before obtaining a marketing authorisation.
16/09/2024